Shortening the duration of therapy for chronic hepatitis C infection.

about

Shortening Treatment for Hepatitis C Virus Infection.

P2860

Q55340857-FD5405F4-B901-43FB-BC7C-052B10ABE96F

P2860

Shortening the duration of therapy for chronic hepatitis C infection.

Item

http://www.wikidata.org/entity/Q38627508

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Shortening the duration of therapy for chronic hepatitis C infection.

@en

type

Item

label

Shortening the duration of therapy for chronic hepatitis C infection.

@en

prefLabel

Shortening the duration of therapy for chronic hepatitis C infection.

@en

P1476

Shortening the duration of therapy for chronic hepatitis C infection.

@en

P2093

Benjamin Emmanuel

http://www.w3.org/2001/XMLSchema#string

Eleanor M Wilson

http://www.w3.org/2001/XMLSchema#string

George Lau

http://www.w3.org/2001/XMLSchema#string

Thomas R O'Brien

http://www.w3.org/2001/XMLSchema#string

P2860

Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States

Modelling hepatitis C therapy--predicting effects of treatment

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Effect of medication dosing frequency on adherence in chronic diseases.

Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C

Treatment of hepatitis C: a systematic review.

P304

832-836

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S2468-1253(17)30053-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shyam Kottilil

P577

2017-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28802815

http://www.w3.org/2001/XMLSchema#string

P932

5737004

http://www.w3.org/2001/XMLSchema#string

Shortening the duration of therapy for chronic hepatitis C infection.

about

P2860

P2860

Shortening the duration of therapy for chronic hepatitis C infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932